WallStSmart

Abbott Laboratories (ABT)vsenVVeno Medical Corp (NVNO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ABT leads profitability with a 13.9% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

NVNO

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -2.51
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$70.96

Current Price

$93.93

$22.97 premium

UndervaluedFair: $70.96Overvalued

Intrinsic value data unavailable for NVNO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$164.43B9/10

Large-cap with strong market position

NVNO2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

ABT2 concerns · Avg: 3.0/10
P/E RatioValuation
26.7x4/10

Moderate valuation

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

NVNO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.41 suggests the stock is reasonably priced for its growth.

Bull Case : NVNO

The strongest argument for NVNO centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, EPS Growth.

Bear Case : NVNO

The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

NVNO carries more volatility with a beta of 1.09 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (54/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

enVVeno Medical Corp

HEALTHCARE · MEDICAL DEVICES · USA

enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.

Want to dig deeper into these stocks?